bluebird bio, Inc. BLUE reported a loss of $2.72 per share in the fourth quarter of 2018, narrower than the Zacks Consensus Estimate of a loss of $2.83 but wider than the year-ago quarter’s loss of $2.52. The wider-than-expected year-over-year loss was due to higher research & development (R&D), and general & administrative (G&A) expenses on lower revenues.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,